Hepatitis B Virus

Positive Phase III Results From Novel Two-Dose Vaccine Reported

Published in Vaccine Weekly, January 30th, 2002

Rhein Biotech, N.V., and Corixa Corporation announced positive preliminary efficacy results of a Phase III clinical trial with a novel two-dose hepatitis B vaccine.

The new vaccine is based on Rhein Biotech's Hansenula polymorpha yeast based recombinant hepatitis B antigen (HBsAg), the active ingredient of commercially approved hepatitis B vaccines (Hepavax-Gene, AgB, Biovac B), and Corixa's RC-529 synthetic adjuvant.

The hepatitis B vaccines currently commercially available generally need three injections for full protection. Results of the primary efficacy analyses showed that there were significantly more individuals seroprotected after two...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2002-01-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry